Johnson & Johnson announced that CAPLYTA (lumateperone) met primary and key secondary endpoints in a Phase 3 study for treating manic episodes in bipolar I disorder, showing significant symptom improvement as early as Day 3 and sustained through Week 3. The study's positive results, alongside another Phase 3 trial, support a planned FDA submission to expand CAPLYTA's use to bipolar mania, complementing its existing approvals for bipolar depression and schizophrenia. CAPLYTA was well-tolerated with a safety profile consistent with prior studies, offering a promising treatment option for rapid symptom control in bipolar mania.
As of Nov 10, 2026 19:43 WIB, Johnson & Johnson (JNJ) shares are trading at USD 285.00 on Pluang, showing a 1.02% increase in the last day. The stock's market capitalization stands at $679.13 billion, reflecting strong investor interest. Pluang users currently favor buying, with 59% of order activity directed towards purchases.
Following the 2026 midterm elections resulting in a divided U.S. government, four dividend-paying blue-chip stocks—Duke Energy, Procter & Gamble, Johnson & Johnson, and JPMorgan Chase—are highlighted for their resilience amid legislative gridlock. Th...
Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...
Three dividend stocks from healthcare, real estate, and energy sectors—Johnson & Johnson, Realty Income, and Chevron—stand out for their reliable dividends supported by strong cash flow and manageable debt. Johnson & Johnson boasts 64 years of consec...
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
